No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 4,890,151 | 5,410,415 | 5,659,922 | 5,894,231 | 6,028,364 | 5,821,815 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 149,253 | 128,377 | 159,880 | 8,566 | 170,309 | -158,472 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Kolon Corporation, established in 1957 and headquartered in Gwacheon, South Korea, operates as a diversified conglomerate. Its core activities include providing strategic support and management for its affiliated enterprises, licensing intellectual property, and offering market research and management consulting services globally. The company possesses extensive manufacturing capabilities, producing a broad spectrum of industrial and specialty materials. This includes textile reinforcements like tire cords and airbags, various films (polyester, nylon, and coated), and advanced products such as polyester spunbond, technical yarns, aramid products, and membranes. Kolon also manufactures DFR materials, overcoats, beads, and a diverse range of resins, including hydrocarbon, phenolic, epoxy, PU/TPU products, and glass-reinforced plastic (GRP) pipes. Furthermore, it is a key producer of nylon and polyester fibers, alongside a wide array of woven, knit, and functional fabrics. Beyond manufacturing, Kolon actively trades in steel, natural resources, and chemicals. Its construction and engineering divisions undertake residential, industrial plant, civil engineering, and environmental projects. The company also develops and supplies specialized automotive components like car seat modules, fabrics, and car mats, in addition to producing artificial turfs, polypropylene staple fibers, bicomponent staple fiber, GEONIC, Cuprus, HeaTex, and polyester filaments. In the leisure and real estate sectors, Kolon manages hotels, condominiums, and golf resorts, spearheads property development, and operates a shopping mall, a pet theme park, and unique themed toilets. Its significant presence in healthcare involves manufacturing over-the-counter medicines (such as the painkiller TRAMOL sustained relief), active pharmaceutical ingredients, and biopharmaceuticals like Tissuegene, complemented by a network of approximately 150 W-Store drugstores. Kolon's diversified portfolio further includes operating Sweet Meal cafés offering pastries and beverages, supplying antimicrobial products, and providing various resin types (PA, PBT, POM/base and compound). It also engages in hardware and software retail, delivers IT and business process outsourcing, and offers IT convergence services. The company is deeply involved in water-related businesses, encompassing sewage and wastewater treatment, the development of associated materials, systems, and equipment, and the operation of water treatment facilities, alongside industrial supply retail.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Kolon Corporation (002025.KS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Kolon Corporation, established in 1957 and headquartered in Gwacheon, South Korea, operates as a diversified conglomerate. Its core activities include providing strategic support and management for its affiliated enterprises, licensing intellectual property, and offering market research and management consulting services globally. The company possesses extensive manufacturing capabilities, producing a broad spectrum of industrial and specialty materials. This includes textile reinforcements like tire cords and airbags, various films (polyester, nylon, and coated), and advanced products such as polyester spunbond, technical yarns, aramid products, and membranes. Kolon also manufactures DFR materials, overcoats, beads, and a diverse range of resins, including hydrocarbon, phenolic, epoxy, PU/TPU products, and glass-reinforced plastic (GRP) pipes. Furthermore, it is a key producer of nylon and polyester fibers, alongside a wide array of woven, knit, and functional fabrics. Beyond manufacturing, Kolon actively trades in steel, natural resources, and chemicals. Its construction and engineering divisions undertake residential, industrial plant, civil engineering, and environmental projects. The company also develops and supplies specialized automotive components like car seat modules, fabrics, and car mats, in addition to producing artificial turfs, polypropylene staple fibers, bicomponent staple fiber, GEONIC, Cuprus, HeaTex, and polyester filaments. In the leisure and real estate sectors, Kolon manages hotels, condominiums, and golf resorts, spearheads property development, and operates a shopping mall, a pet theme park, and unique themed toilets. Its significant presence in healthcare involves manufacturing over-the-counter medicines (such as the painkiller TRAMOL sustained relief), active pharmaceutical ingredients, and biopharmaceuticals like Tissuegene, complemented by a network of approximately 150 W-Store drugstores. Kolon's diversified portfolio further includes operating Sweet Meal cafés offering pastries and beverages, supplying antimicrobial products, and providing various resin types (PA, PBT, POM/base and compound). It also engages in hardware and software retail, delivers IT and business process outsourcing, and offers IT convergence services. The company is deeply involved in water-related businesses, encompassing sewage and wastewater treatment, the development of associated materials, systems, and equipment, and the operation of water treatment facilities, alongside industrial supply retail.
